BioCryst Pharmaceuticals (BCRX) stock forecast for 2024. Forecast tables and graphs.







A Comprehensive Guide to RoadRunner Auto Transport Services

October 22, 2024 A Comprehensive Guide to RoadRunner Auto Transport Services

If you want to ship your car from one city to another, why not hire the experts to do everything for you? They…
Mastering Trading Indicators: Your Essential Toolkit For Success

October 3, 2024 Mastering Trading Indicators: Your Essential Toolkit For Success

Often investors struggle to identify profitable trades consistently. Trading indicators provide essential data to guide trading decisions. This article explains key indicators and…
Maximizing Profits: When is the Right Time to Sell Your Business?

April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?

Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
Improve Your Financial Status: A How-To Guide

April 12, 2024 Improve Your Financial Status: A How-To Guide

Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…

BioCryst Pharmaceuticals (BCRX) stock forecast for 2024

Updated: November 6, 2024 (07:27)

Sector: Healthcare

The share price of BioCryst Pharmaceuticals, Inc. (BCRX) now

What analysts predict: $14.64
52-week High/Low: $8.88 / $4.03

50/200 Day Moving Average: $7.84 / $6.42

This figure corresponds to the Average Price over the previous 50/200 days. For BioCryst Pharmaceuticals stocks, the 50-day moving average is the resistance level today.

For BioCryst Pharmaceuticals stocks, the 200-day moving average is the resistance level today.

Are you interested in BioCryst Pharmaceuticals, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the BioCryst Pharmaceuticals stock price in 2024. How much will one BioCryst Pharmaceuticals share be worth in 2024? Is it worth taking profit / loss on BCRX stock now or waiting? What are analysts' forecasts for BioCryst Pharmaceuticals stock?

We forecast BioCryst Pharmaceuticals stock performance using neural networks based on historical data on BCRX stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. This corporation stock prediction results are shown below and presented as a graph, table and text information.

BioCryst Pharmaceuticals, Inc. stock forecasts are adjusted once a day based on the closing price of the previous trading day.

The minimum target price for BioCryst Pharmaceuticals analysts is $14.64. Today 200 Day Moving Average is the support level (6.42 $). 50 Day Moving Average is the support level (7.84 $).




Historical and forecast chart of BioCryst Pharmaceuticals, Inc. stock

The chart below shows the historical price of BioCryst Pharmaceuticals stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the BCRX stock price can be found in the table below.


BioCryst Pharmaceuticals, Inc., a biotech company, is dedicated to the discovery of oral and small molecule drugs. The company markets injections of peramivir, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza, under the names RAPIVAB, ALPIVAB, RAPIACTA and PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for the treatment of peripheral T-cell lymphoma.

Trending Themes in the Healthcare Sector

BioCryst Pharmaceuticals (BCRX) Forecast for 2024

Month Target Pes. Opt. Vol., %
Dec 7.17 6.63 7.53 11.89 %

BioCryst Pharmaceuticals information and performance

BioCryst Pharmaceuticals Address

4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, US

Market Capitalization: 1 522 325 000 $

Market capitalization of the BioCryst Pharmaceuticals, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of BCRX shares in the company outstanding by the market price of one share.

EBITDA: -52 709 000 $

EBITDA of BioCryst Pharmaceuticals is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: -0.28

Price/earnings to growth

DPS: None

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: None

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -0.61

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 0.325
Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: -

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 5.02

Enterprise Value (EV) /Revenue

EV To EBITDA: -12.2

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 206886000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

BioCryst Pharmaceuticals price target for 2024 by month


Target values for the price of one BioCryst Pharmaceuticals share for Dec 2024.

The weighted average target price per BioCryst Pharmaceuticals share in Dec 2024 is: 7.17.
In Dec, the Positive dynamics for BioCryst Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 11.895% volatility is expected.
Pessimistic target level: 6.63
Optimistic target level: 7.53



Related stocks from Healthcare sector


Disclaimer: